CSIMarket Company Name, Ticker, Suppliers, else..
 
Trisalus Life Sciences Inc   (NASDAQ: TLSI)
 
Price: $5.0000 $0.02 0.402%
Day's High: $5.125 Week Perf: 1.01 %
Day's Low: $ 4.92 30 Day Perf: 2.67 %
Volume (M): 86,869 52 Wk High: $ 7.95
Volume (M$): $ 0 52 Wk Avg: $4.81
Open: $4.92 52 Wk Low: $2.20



 Market Capitalization (Millions $) 262
 Shares Outstanding (Millions) 52
 Employees 102
 Revenues (TTM) (Millions $) 44
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) 43
 Capital Exp. (TTM) (Millions $) 0

Business Description


Trisalus Life Sciences Inc is a medical technology company that focuses on developing innovative solutions for the treatment of liver cancer. They specialize in the creation of minimally invasive therapy options that provide targeted treatment directly to tumor cells while minimizing damage to healthy tissues. Their flagship product is the Pressure-Enabled Drug Delivery (PEDD) technology, which utilizes precision-guided infusion to deliver therapeutic agents deep within solid tumors. Trisalus Life Sciences Inc aims to improve patient outcomes and enhance quality of life through their advanced therapies for liver cancer treatment.


   Company Address: 6272 W 91st Ave Westminster 80031 CO
   Company Phone Number: 321-5212   Stock Exchange / Ticker: NASDAQ TLSI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ANIK   -1.37%    
MAGAA   -1.37%    
NEPH   -10.77%    
AMGN        1.11% 
BMY        0.36% 
GILD        3.65% 
• View Complete Report
   



Business Update

Augmenting Tumor Treatment TriSalus Unveils Breakthrough Technology for Uterine Fibroids,

Published Mon, Nov 10 2025 2:39 PM UTC

In the ever-evolving landscape of medical technology, TriSalus Life Sciences continues to push the boundaries of cancer treatment. This innovative oncology company, known for its commitment to integrating novel delivery technologies with conventional therapies, is turning the spotlight on its promising TriNav Infusion System. The upcoming virtual event on November 12, 2025, ...
Business Update

Transforming Oncology TriSalus Life Sciences Unveils Innovations and Financial Progress Amid Upcoming Investor Engage...

Published Fri, Aug 29 2025 6:40 PM UTC

Transforming Oncology: TriSalus Life Sciences Unveils Innovations and Financial Progress Amid Upcoming Investor Engagements TriSalus Life Sciences Inc. (Nasdaq: TLSI), an emerging leader in oncology focused on redefining the treatment landscape for solid tumors, has been making significant strides in both its technological advancements and financial performance. Headquartere...
Business Update

Advancements in Cancer Treatment TriSalus Reports Improved Drug Delivery Method for Solid Tumors

Published Mon, Sep 23 2024 1:47 PM UTC

In a significant development in the field of oncology, TriSalus Life Sciences, Inc. announced the publication of new research that highlights the effectiveness of its innovative drug delivery system in targeting solid tumors. The study, recently published in the Journal of Vascular and Interventional Radiology , provides evidence that the Pressure-Enabled Drug Delivery (PED...
Business Update

TriSalus Reports Strong Q2 2024 Growth and Strategic Developments in Cancer Treatment

Published Thu, Aug 15 2024 1:47 PM UTC

TriSalus Reports Q2 2024 Financial Results and Business Update In a recent announcement, TriSalus Life Sciences, a leader in the development of innovative therapies for solid tumors, shared its financial results for the second quarter of 2024 and provided insight into its strategic initiatives. The report highlighted both the robust financial performance of the company and ...
Business Update

TriSalus Life Sciences Completes Exchange Offer and Consent Solicitation for Warrants, Advancing Novel Cancer Treatme...

Published Thu, Jun 27 2024 1:54 AM UTC

TriSalus Life Sciences Announces Results of Exchange Offer and Consent Solicitation for WarrantsTriSalus Life Sciences Inc., an oncology company focused on improving treatment for patients with liver and pancreatic tumors, has announced the expiration and results of its exchange offer and consent solicitation relating to its warrants. The company aims to integrate its innova...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 5.92
Price to Sales (Expected) -
Price to Book 20.42
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.8
Working Capital Ratio 5.78
Leverage Ratio (MRQ) 4.54
Total Debt to Equity 2.58
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.44 $
Revenues (TTM) 0.84 $
Cash Flow (TTM) 0.83 $
Cash 1.08 $
Book Value 0.24 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 433,167
Net Income per Employee (TTM) -449,304
Receivable Turnover Ratio (TTM) 7.91
Inventory Turnover Ratio (TTM) 1.72
Asset Turnover Ratio (TTM) 0.97

Profitability Ratios Current
Gross Margin (MRQ) 88.46 %
Operating Margin (MRQ) -97.02 %
Net Margin (MRQ) 17.75 %
Net Cash Flow Margin (MRQ) 412.55 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Trisalus Life Sciences Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.